Approvals (Drugs@FDA)

NAVITRUX

AVYXA HOLDINGS · FOSAPREPITANT DIMEGLUMINE

NDA220436Drug (NDA)Prescription
Open FDA's page for this record
Application number
NDA220436
Sponsor name
AVYXA HOLDINGS
Submissions
  1. Submission type
    ORIG
    Submission number
    1
    Submission status
    AP
    Submission status date
    20260624
    Review priority
    STANDARD
    Submission class code
    TYPE 5
    Submission class code description
    Type 5 - New Formulation or New Manufacturer
    Application docs
    1. ID
      86357
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220436Orig1s000ltr.pdf
      Date
      20260626
      Type
      Letter
    2. ID
      86384
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220436Orig1s000lbl.pdf
      Date
      20260629
      Type
      Label
Products
  1. Product number
    001
    Reference drug
    Yes
    Brand name
    NAVITRUX
    Reference standard
    Yes
    Dosage form
    POWDER
    Route
    INTRAVENOUS
    Marketing status
    Prescription
    Active ingredients
    1. Name
      FOSAPREPITANT DIMEGLUMINE
      Strength
      EQ 150MG BASE/VIAL
Harmonized identifiers (openFDA)
Application number
NDA220436
Brand name
NAVITRUX
Generic name
FOSAPREPITANT
Manufacturer name
AVYXA Pharma, LLC
Product NDC
83831-153
Product type
HUMAN PRESCRIPTION DRUG
Route
INTRAVENOUS
Substance name
FOSAPREPITANT DIMEGLUMINE
RxCUI
1731077, 2745874
SPL ID
bc79f63b-8a05-41b5-a349-f71f1313e791
SPL set ID
a41b7c3a-1376-43a7-b5b9-6ba2eba1e169
Package NDC
83831-153-01
UNII
D35FM8T64X
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.